P2 Science
Designs and manufactures renewable specialty ingredients for personal care, fragrance, and performance materials
$23MUndisclosed
Role not disclosedSP
Sofinnova Partners
Activity from announced rounds
Activity in this selectionMay 31, 2026 · May 1, 2026
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $256.1M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionCellCentric
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
$220MSeries D
Role not disclosedSignadori Bio
Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage
€11.1MSeed+
Role not disclosed